8.37 USD
+0.01 (+0.12%)
8.4 USD
+0.03 (+0.36%)
ChartMill assigns a Buy % Consensus number of 78% to CNCE. The Buy consensus is the weighted average rating of the current analysts ratings.
- Analysts have set a mean price target forecast of 11.9. This target is 42.17% above the current price.
- CNCE was analyzed by 11 analysts. The buy percentage consensus is at 78. So analysts seem to be have mildly positive about CNCE.
- In the previous month the buy percentage consensus was at a similar level.
- CNCE was analyzed by 11 analysts, which is quite many. So the average rating should be quite meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2023-01-20 | JonesTrading | Downgrade | Buy -> Hold |
| 2022-09-13 | Truist Securities | Maintains | Buy |
| 2022-08-25 | JonesTrading | Initiate | Buy |
| 2021-10-05 | Mizuho | Maintains | Buy |
CONCERT PHARMACEUTICALS INC / CNCE FAQ
Can you provide the average price target for CONCERT PHARMACEUTICALS INC stock?
11 analysts have analysed CNCE and the average price target is 11.9 USD. This implies a price increase of 42.17% is expected in the next year compared to the current price of 8.37.
How do analysts rate CONCERT PHARMACEUTICALS INC (CNCE)?
The consensus rating for CONCERT PHARMACEUTICALS INC (CNCE) is 78.1818 / 100 . This indicates that analysts generally have a positive outlook on the stock.
How many analysts cover CONCERT PHARMACEUTICALS INC (CNCE) stock?
The number of analysts covering CONCERT PHARMACEUTICALS INC (CNCE) is 11.